CUSIP 29479A108COMERASQ4 2025
35 filings · latest Feb 17, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 22.73M | $84.55M |
| 2 | Vr Adviser, LLC | 17.86M | $66.43M |
| 3 | Blackrock, Inc. | 15.60M | $58.02M |
| 4 | Suvretta Capital Management, LLC | 14.50M | $53.95M |
| 5 | Paradigm Biocapital Advisors LP | 14.16M | $52.67M |
| 6 | Logos Global Management LP | 13.00M | $48.36M |
| 7 | Vanguard Group Inc | 12.81M | $47.66M |
| 8 | Arch Venture Management, LLC | 11.06M | $41.13M |
| 9 |
| 4 | Aug 14, 2025 | T. Rowe Price Investment Management, Inc. | 13G/A | 7.2% | 20.33M | SEC |
| 5 | Aug 14, 2025 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.3% | 15.04M | SEC |
| 6 | Aug 14, 2025 | Logos Global Management LP | 13G | 5.3% | 15.10M | SEC |
| 7 | Aug 13, 2025 | Suvretta Capital Management, LLC | 13G | 5.1% | 14.50M | SEC |
| 8 | May 15, 2025 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 8.0% | 22.58M | SEC |
| 9 | Feb 13, 2025 | Suvretta Capital Management, LLC | 13G/A | 4.4% | 12.32M | SEC |
| 10 | Feb 12, 2025 | Novartis Pharma AG | 13G/A | 4.4% | 12.31M | SEC |
See the full Schedule 13D/13G history for Erasca Inc.
Unlock full history| Vivo Capital, LLC |
| 9.27M |
| $34.50M |
| 10 | Siren, L.L.C. | 8.76M | $32.58M |